MedinCell S.A. Logo

MedinCell S.A.

Develops long-acting injectable therapies using proprietary technology to impact global health.

MEDCL | PA

Overview

Corporate Details

ISIN(s):
FR0004065605
LEI:
969500R79U6PXCL2FF46
Country:
France
Address:
3 RUE DES FRERES LUMIERE, 34830 JACOU
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MedinCell S.A. is a clinical and commercial-stage pharmaceutical company specializing in the development of long-acting injectable (LAI) therapies. Leveraging its proprietary drug delivery technology, the company develops a diverse portfolio of controlled-release products across various therapeutic areas. This innovative approach is designed to enhance treatment efficacy, improve patient compliance, and reduce the overall burden of care by providing sustained therapeutic effects from a single injection. MedinCell collaborates with global pharmaceutical partners to advance its pipeline and address unmet medical needs, with a core mission to impact global health by making treatments more efficient and accessible.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-05 13:46
Earnings Release
Informations privilégiées / Autres communiqués
French 310.2 KB
2025-11-05 13:46
Earnings Release
Inside Information / Other news releases
English 215.5 KB
2025-09-22 07:30
Regulatory Filings
Informations privilégiées / Autres communiqués
French 359.5 KB
2025-09-22 07:30
Regulatory Filings
Inside Information / Other news releases
English 263.8 KB
2025-09-12 07:30
Board/Management Information
Informations privilégiées / Autres communiqués
French 189.0 KB
2025-09-12 07:30
Board/Management Information
Inside Information / Other news releases
English 178.3 KB
2025-09-10 21:41
Regulatory Filings
Informations privilégiées / Autres communiqués
French 171.5 KB
2025-09-10 21:41
Regulatory Filings
Inside Information / Other news releases
English 168.1 KB
2025-06-17 17:45
Annual / Quarterly Financial Statement
Inside Information / News release on accounts, results
English 405.2 KB
2025-06-17 17:45
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 395.7 KB
2025-06-10 18:00
Report Publication Announcement
Inside Information / Other news releases
English 185.6 KB
2025-06-10 18:00
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 192.0 KB
2025-06-06 18:00
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 183.7 KB
2025-05-28 18:00
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 183.1 KB
2025-05-28 18:00
Regulatory Filings
Inside Information / Other news releases
English 156.6 KB

Automate Your Workflow. Get a real-time feed of all MedinCell S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MedinCell S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MedinCell S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-05-02 N/A Other Sell 60,000 600,006.00 EUR

Peer Companies

NKMAX Co., Ltd. Logo
Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.
South Korea
182400
NLS Pharmaceutics Ltd. Logo
Developing therapies for rare CNS disorders, specializing in narcolepsy and sleep-wake issues.
United States of America
NLSP
NovaBay Pharmaceuticals, Inc. Logo
Develops clinically-proven anti-infective therapies for eyecare, skincare, and wound care.
United States of America
NBY
Novacyt Logo
Designs and supplies molecular diagnostic tests and PCR kits for human, veterinary, and food safety.
France
ALNOV
Novartis AG Logo
Develops and markets innovative medicines globally using advanced science and technology.
Switzerland
NOVN
NOVAVAX INC Logo
Develops and commercializes nanoparticle vaccines for serious infectious diseases.
United States of America
NVAX
Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.
South Korea
229500
Novo Nordisk Logo
Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.
Denmark
NOVO
NRX Pharmaceuticals, Inc. Logo
Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.
United States of America
NRXP
NuCana plc Logo
Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.
United States of America
NCNA

Talk to a Data Expert

Have a question? We'll get back to you promptly.